ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) completed the sale of its subsidiary, Shanghai Zhangtou Yaoxin Technology Development, to Shanghai Zhangjiang Group, according to a Friday Hong Kong bourse filing.
The biopharmaceutical firm has already received the first two payment installments of 66.2 million yuan and is set to receive the last one within 10 business days from the date on which the adjusted amount is determined.
The disposal was first announced on Dec. 30, 2024, with ImmuneOnco agreeing to sell the subsidiary for up to 98.2 million yuan.
Shanghai Zhangtou Yaoxin Technology Development was formed to hold an industrial property-holding company in Shanghai.
Shares of the company were down nearly 15% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.